Homologous recombination deficiency (HRD) arises when defects in
DNA repair pathways occur, leading to genomic instability. HRD
status is an emerging therapeutic biomarker; NGS assays that
measure it can be used to stratify ovarian and breast cancer patients
and determine eligibility for clinical trials, and PARP inhibitor and
platinum-based therapies. Seraseq® FFPE HRD reference materials
were developed to cover a range of genomic instability scores (GIS)
to help NGS HRD assay validation and development.
Download this scientific poster to learn more about a multi-site evaluation across various platforms of our high-positive, low-positive, and negative HRD reference materials.
To download, fill out the form and you will receive an email with the content.
